{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T21:00:56Z","timestamp":1780174856674,"version":"3.54.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018895","name":"National Institute of Technology, Raipur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bmcl.2026.130678","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:03:14Z","timestamp":1777647794000},"page":"130678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design and synthesis of [1,2,4]triazolo[3,4-b]thiadiazine-1,2,4-oxadiazoles as EGFR tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"138","author":[{"given":"Jallala","family":"Raju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Kola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagadeesh Kumar","family":"Ega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bmcl.2026.130678_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130678_bb0010","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmcl.2026.130678_bb0015","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1039\/D5MD00103J","article-title":"Design, synthesis, and evaluation of novel heterocyclic scaffolds as anticancer agents","volume":"16","author":"Bandgar","year":"2025","journal-title":"RSC Med Chem"},{"issue":"5\u20136","key":"10.1016\/j.bmcl.2026.130678_bb0020","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4103\/ijmr.ijmr_1821_22","article-title":"Cancer incidence estimates for 2022 and projection for 2025: results from National Cancer Registry Programme, India","volume":"156","author":"Sathishkumar","year":"2022","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.bmcl.2026.130678_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211034366","article-title":"New approaches and procedures for cancer treatment: current perspectives","volume":"9","author":"Debela","year":"2021","journal-title":"SAGE Open Med"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130678_bb0030","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.3390\/curroncol30030239","article-title":"Stage III non\u2013small-cell lung cancer: an overview of treatment options","volume":"30","author":"Petrella","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.bmcl.2026.130678_bb0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130678_bb0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases\u2014the major drug targets of the twenty-first century","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat Rev Drug Discov"},{"issue":"34","key":"10.1016\/j.bmcl.2026.130678_bb0045","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1016\/j.biomaterials.2013.07.100","article-title":"Epidermal growth factor receptor targeting in cancer: a review of trends and strategies","volume":"34","author":"Yewale","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.bmcl.2026.130678_bb0050","article-title":"Understanding the roles of PD-1\/PD-L1 in the tumor microenvironment and therapeutic implications in cancer","volume":"161","author":"Liang","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmcl.2026.130678_bb0055","article-title":"Design and synthesis of novel heterocyclic compounds with potential anticancer activity","volume":"154","author":"Shetty","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2026.130678_bb0060","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2026.130678_bb0065","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrc749","article-title":"DNA and its associated processes as targets for cancer therapy","volume":"2","author":"Hurley","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2026.130678_bb0070","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14737140.2018.1527688","article-title":"A comprehensive review of PI3K\u2013AKT\u2013mTOR pathway inhibitors in cancer therapy","volume":"18","author":"Kannaiyan","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.bmcl.2026.130678_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112652","article-title":"An insight on medicinal attributes of benzimidazole scaffold: a review","volume":"205","author":"Aggarwal","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130678_bb0080","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ejmech.2013.01.060","article-title":"Recent advances in the structural modification of benzimidazole for various biological targets","volume":"63","author":"Khan","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130678_bb0085","article-title":"Synthesis and biological evaluation of novel 1,2,3-triazole derivatives as potential anticancer agents","volume":"109","author":"Omar","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2026.130678_bb0090","article-title":"Design, synthesis, and evaluation of quinazoline\u2013triazole hybrids as potential anticancer agents","volume":"208","author":"Ma","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130678_bb0095","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/jcb.29442","article-title":"Naphthoquinone derivatives as potent anticancer agents targeting apoptosis and autophagy pathways","volume":"121","author":"Liu","year":"2020","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bmcl.2026.130678_bb0100","doi-asserted-by":"crossref","first-page":"21869","DOI":"10.1039\/D1NJ03892C","article-title":"Novel triazole\u2013benzothiazole hybrids as antiproliferative agents: synthesis, cytotoxic evaluation, and molecular docking","volume":"45","author":"Yang","year":"2021","journal-title":"New J Chem"},{"key":"10.1016\/j.bmcl.2026.130678_bb0105","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.3390\/molecules24244471","article-title":"Design, synthesis, and anticancer evaluation of new thiazole derivatives","volume":"24","author":"Boraei","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130678_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s41061-022-00365-x","article-title":"Recent advances in oxadiazole-based heterocycles as potential therapeutic agents","volume":"380","author":"Aggarwal","year":"2022","journal-title":"Top Curr Chem"},{"key":"10.1016\/j.bmcl.2026.130678_bb0115","article-title":"Microwave-assisted synthesis of novel heterocyclic scaffolds with anticancer potential","volume":"146","author":"Praveen","year":"2024","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmcl.2026.130678_bb0120","article-title":"Novel benzothiazine\u2013triazole derivatives: synthesis, crystal structure, and biological evaluation","volume":"1306","author":"Chirra","year":"2024","journal-title":"J Mol Struct"},{"issue":"22","key":"10.1016\/j.bmcl.2026.130678_bb0125","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.3390\/ijms21228692","article-title":"Groundbreaking anticancer activity of highly diversified oxadiazole scaffolds","volume":"21","author":"Benassi","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10.1016\/j.bmcl.2026.130678_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127438","article-title":"Design, synthesis, biological evaluation and molecular docking of new uracil analogs\u20131,2,4-oxadiazole hybrids as potential anticancer agents","volume":"30","author":"El Mansouri","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130678_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103828","article-title":"Design and synthesis of 3,5-substituted 1,2,4-oxadiazoles as catalytic inhibitors of human DNA topoisomerase II\u03b1","volume":"99","author":"Loboda","year":"2020","journal-title":"Bioorg Chem"},{"issue":"7","key":"10.1016\/j.bmcl.2026.130678_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200045","article-title":"A comprehensive review of recent advances in the biological activities of 1,2,4-oxadiazoles","volume":"355","author":"Hendawy","year":"2022","journal-title":"Arch Pharm"},{"key":"10.1016\/j.bmcl.2026.130678_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.132218","article-title":"Design and synthesis of new triarylimidazole derivatives as dual inhibitors of BRAFV600E\/p38\u03b1 with potential antiproliferative activity","volume":"1253","author":"Youssif","year":"2022","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmcl.2026.130678_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105124","article-title":"Rational design-aided discovery of novel 1,2,4-oxadiazole derivatives as potential EGFR inhibitors","volume":"114","author":"Unadkat","year":"2021","journal-title":"Bioorg Chem"},{"issue":"41","key":"10.1016\/j.bmcl.2026.130678_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202504584","article-title":"Imidazole\u2013oxadiazole-linked Sulfonyl-1,2,3-triazoles as potential EGFR inhibitors for lung Cancer treatment","volume":"10","author":"Dodlapati","year":"2025","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bmcl.2026.130678_bb0160","doi-asserted-by":"crossref","first-page":"11273","DOI":"10.1002\/slct.201801857","article-title":"A novel one-pot synthesis of heterocyclic frameworks via metal-free protocol","volume":"3","author":"Zarei","year":"2018","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bmcl.2026.130678_bb0165","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1002\/slct.202101820","article-title":"Synthesis of new heterocyclic triazole\u2013benzimidazole hybrids with potential biological activity","volume":"6","author":"Sagam","year":"2021","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bmcl.2026.130678_bb0170","article-title":"Structural characterization and biological assessment of novel triazole derivatives","volume":"1312","author":"Johnpasha","year":"2024","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmcl.2026.130678_bb0175","article-title":"Synthesis and molecular docking studies of novel heterocyclic scaffolds as potential inhibitors","volume":"1320","author":"Udayasree","year":"2025","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmcl.2026.130678_bb0180","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jhet.4788","article-title":"Design, synthesis, and characterization of benzimidazole-based heterocycles with anticancer potential","volume":"61","author":"Samala","year":"2024","journal-title":"J Heterocyclic Chem"},{"key":"10.1016\/j.bmcl.2026.130678_bb0185","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1080\/10406638.2023.2247127","article-title":"Novel tricyclic aromatic compounds: synthesis, spectral studies, and biological evaluation","volume":"44","author":"Johnpasha","year":"2024","journal-title":"Polycycl Aromat Compd"},{"key":"10.1016\/j.bmcl.2026.130678_bb0190","article-title":"Development of novel heterocyclic scaffolds with potent anticancer activity","volume":"10","author":"Peddapelli","year":"2025","journal-title":"ChemistrySelect"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T20:24:16Z","timestamp":1780172656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26001459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"alternative-id":["S0960894X26001459"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130678","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of [1,2,4]triazolo[3,4-b]thiadiazine-1,2,4-oxadiazoles as EGFR tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130678"}}